Mumbai-based pharmaceutical company, Shashvi Remedies, has introduced an innovative formulation that has the potential to transform breast cancer treatment. This breakthrough represents an important step forward in tackling one of the most widespread and lethal diseases, especially affecting women. Breast cancer has now overtaken lung cancer as the most prevalent malignancy worldwide, resulting in millions of deaths annually.

The World Health Organisation (WHO) reports that breast cancer accounts for one in five cancer diagnoses globally. Recent data indicates that breast cancer accounts for over 25% of all cancer cases in women worldwide, and over 30% in India. Projections indicate an annual global cancer incidence rate of 11.6%, underscoring the urgent need for effective treatments.

Shashvi Remedies, led by founders Sonal Bansal, A.K. Bansal, and co-founders Birendra Singh Negi, Dr. Kiran, and Digant Sharma, has committed ten years to thorough research, development, and testing. Clinical testing has yielded a formulation that demonstrates impressive effectiveness and safety in the fight against breast cancer.

The formulation eliminated more than 80% of cancerous cells within a 72-hour period, according to research on the MCF7 human breast cancer cell line. Additional in-vivo safety studies conducted at a well-known government institute in Mumbai validated the formulation’s safety for healthy cells. The formulation specifically targets cancer cells without harming healthy tissue, marking a significant advancement in cancer treatment.

“This formulation is safe and has the potential to save countless lives,” stated Sonal Bansal, Director and Spokesperson for Shashvi Remedies. “After more than ten years of thorough research and testing, this accomplishment signifies a victory for the international medical community and, most crucially, for cancer patients around the globe. Our unique method focuses on breast cancer cells while preserving healthy tissue. We envision a future where we can both treat and prevent cancer through the development of a universal breast cancer vaccine. This breakthrough offers hope for breast cancer patients and their families, marking an important advancement for the pharmaceutical industry overall.

The journey of the formulation started in 2018 with initial in vitro studies and reached its conclusion in 2024 with additional validation. The results highlight its ability to effectively tackle the growing global challenge of breast cancer.

According to the WHO, breast cancer emerged as the most common cancer diagnosis among women globally in 2020. This development presents a hopeful new option for treatment, impacting millions of lives. Shashvi Remedies’ breakthrough showcases both innovative science and the strength of perseverance and vision in the battle against cancer.

This formulation's progress toward clinical deployment marks a significant turning point for breast cancer treatment, bringing renewed hope to patients and their families around the globe.  The global medical community is making steady progress toward achieving the goal of a universal breast cancer vaccine.